An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: 'Bridging the gap between laboratory data and patient related outcomes'
Expert Rev Hematol. 2023 Jun 17. doi: 10.1080/17474086.2023.2226858. Online ahead of print.ABSTRACTINTRODUCTION: Until recently the treatment of sickle cell disease (SCD) for a long time has been limited to Hydroxycarbamide alone. SCD is characterized by hemoglobin (Hb) polymerization, hemolysis and ischemia. Voxelotor, a first-in-class Hb modulator that increases Hb-oxygen affinity and reduces RBC polymerization is approved for the treatment of hemolytic anemia in SCD patients.AREAS COVERED: This review is to examine the evidence supporting the laboratory and clinical benefits of voxelotor in SCD. The search keywords: hem...
Source: Expert Review of Hematology - June 17, 2023 Category: Hematology Authors: Baba Pd Inusa Khuthala Mnika Samah Babiker Source Type: research
Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review
The objective was to determine the clinical and economic burden of AF in onco-hematological patients in Europe.AREAS COVERED: A targeted literature review was completed for observational, retrospective and case studies, and reviews on AF in onco-hematology published between January 2010 and 2022 in PubMed, Science Direct, Medes, and IBECS. The search was based on epidemiology, costs, health-related quality of life (HRQoL), disease burden and management, and patient journey. Thirty-one studies fulfilled eligibility criteria. Annual incidence of AF during treatment varies up to 25%, and has increased with first-generation Br...
Source: Expert Review of Hematology - June 12, 2023 Category: Hematology Authors: Fernando Escalante Barrig ón Cristina Bas Boxiong Tang Keri Yang Elisenda Pomares Alejandra Garc ía Nasim Bahar Source Type: research
